May 12, 2005 — ANN ARBOR, Mich. May 12, 2005 -- Although under the radar of some investors, Velcura Therapeutics®, Inc. clearly has been busy since Windhover Information Inc. Review of Emerging Medical Ventures profiled the company in its piece "Drugs that Induce Bone Growth: The Beginning of An Era for Anabolic Bone Forming Agents." So Windhover's Start-Up Forum 2005 will uncover some of the recent achievements and future plans of the biotechnology company that may provide the answer for more than 44 million people who are at risk of osteoporosis, and a potential $65 billion market.

Jan. 5, 2005 — Ann Arbor, Mich. Jan. 5, 2005 – The recent addition of Fred Beyerlein further strengthens the Board of Directors of Velcura Therapeutics®, Inc., a biotechnology company involved in developing new and better therapies for osteoporosis. "As an international leader in the pharmaceutical, fine chemical, biotechnology and advanced materials industries, Fred Beyerlein offers invaluable experience to help us achieve Velcura’s vital mission of speeding research to fight bone disease," said Velcura Therapeutics President and CEO Michael W. Long, Ph.D.

Dec. 13, 2004 — Ann Arbor, Mich. Dec. 13, 2004 -- Velcura Therapeutics®, Inc. has established a new Bone Therapy Evaluation Group to act as a service component of the company and allow rapid testing of potential therapies for osteoporosis and other bone diseases. Dedicated to fighting bone disease, Velcura Therapeutics has pioneered the use of human bone cells as targets for drug discovery applications. The evaluation group will utilize Velcura’s unique cell-based platform technologies to provide rapid drug optimization studies, drug target identification, mechanism of action, and cellular pathways analyses.

July 30, 2004 — Ann Arbor, MICH., July 30, 2004 -- Velcura Therapeutics™, Inc. recently was awarded $1,452,000 to study the mechanisms by which primitive cells develop into mature bone-forming cells. Velcura investigates how human bone cells function as part of its work developing novel therapies for bone diseases such as osteoporosis. The grant was awarded by the National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) based on NIDDK’s interests in endocrinology, metabolic diseases, and stem cells.

July 22, 2004 — ANN ARBOR, MICH., July 22, 2004 – Velcura Therapeutics™, Inc. announced today the development of a custom Affymetrix (Nasdaq: AFFX) GeneChip® array that aids the development of bone disease therapies by enabling researchers to follow global changes in gene expression during human bone formation. Velcura worked with Affymetrix, the world leader in DNA microarray technologies, to design and produce the custom array using Affymetrix’ CustomExpress™ Array Program. This custom GeneChip array, which Velcura hopes will help speed research to help fight osteoporosis and other bone diseases, is available only to Velcura Therapeutics for use within the company for its own studies or that of its strategic partners.